Fenofibrate / simvastatin benefit in dyslipidemia explored

November 1, 2012
Fenofibrate/Simvastatin benefit in dyslipidemia explored
Combination treatment with fenofibrate and simvastatin significantly reduces postprandial triglyceride levels compared with simvastatin alone in all subjects, regardless of fasting triglyceride level, but reduces atherogenic apolipoprotein B48 particles only in those with increased fasting triglyceride levels, according to research published online Oct. 25 in Diabetes Care.

(HealthDay)—Combination treatment with fenofibrate and simvastatin (FENO-S) significantly reduces postprandial (PP) triglyceride (TG) levels compared with simvastatin alone in all subjects, regardless of fasting TG level, but reduces atherogenic apolipoprotein (apo) B48 particles only in those with increased fasting TG levels, according to research published online Oct. 25 in Diabetes Care.

Gissette Reyes-Soffer, M.D., of the Columbia University Medical Center in New York City, and colleagues conducted a study involving a subset of 139 subjects (mean age, 61 years) from the Action to Control in Diabetes lipid study (ACCORD Lipid) to evaluate the effect of combination therapy with FENO-S compared with placebo plus (PL-S) on PP lipid and lipoprotein levels. Primary measures included PP plasma TG, apoB48, and apoCIII, measured over 10 hours after an oral fat load.

The researchers found that the PP TG incremental area under the curve (IAUC) above fasting was 572 and 770 in the FENO-S and PL-S groups, respectively (P = 0.008). In the FENO-S versus the PL-S group, there was a significant reduction in PP apoB48 IAUC. On the day of the study, fasting TG levels correlated with PP TG IAUC for both FENO-S and PL-S groups. For PP TG IAUC, the fibrate effect was constant across the range of fasting TG levels, while for PP apoB48 IAUC, the reduction was only seen when fasting TG levels were increased.

"These results may have implications for interpretation of the overall ACCORD Lipid trial, which suggested benefit from FENO-S only in dyslipidemic individuals," the authors write.

One author disclosed to and Merck Pharmaceuticals, both of which provided the study medications for the ACCORD Lipid trial.

Explore further: The Homburg Cream and Sugar study

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

The Homburg Cream and Sugar study

August 29, 2011

The Homburg Cream and Sugar (HCS) study was designed to determine whether the measurement of postprandial triglyceride in addition to the assessment of glucose tolerance and traditional risk factors might improve the prediction ...

Recommended for you

Engineered hot fat implants reduce weight gain in mice

August 20, 2015

Scientists at the University of California, Berkeley, have developed a novel way to engineer the growth and expansion of energy-burning "good" fat, and then found that this fat helped reduce weight gain and lower blood glucose ...

Promising progress for new treatment of type 1 diabetes

July 30, 2015

New research from Uppsala University shows promising progress in the use of anti-inflammatory cytokine for treatment of type 1 diabetes. The study, published in the open access journal Scientific Reports, reveals that administration ...

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.